Below are some of the most frequently asked questions about Galmed Pharmaceuticals Ltd. If you don't find what you're looking for here, please contact us directly.
16 Tiomkin Street
Tel Aviv, 6578317 Israel
+972.3.693.8448
551 Fifth Avenue
New York, NY 10176
+1.646.780.7605
Galmed does not offer a direct stock purchase program.
The company's fiscal year ends on December 31.
Galmed’s SEC filings are listed under the SEC Filings tab in the Investor Relations section of the Galmed website. You may also read and copy the registration statement and prospectus, including the related exhibits and schedules, and any document we file with the SEC without charge at the SEC’s public reference room at 100 F Street, N.E., Room 1580, Washington, DC 20549. You may also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Room 1580, Washington, DC 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. The SEC also maintains an Internet website that contains reports and other information regarding issuers that file electronically with the SEC. Our filings with the SEC are also available to the public through the SEC’s website.
No. Galmed does not anticipate paying any dividends on its capital stock in the foreseeable future.
Galmed’s transfer agent can be contacted in writing, by phone or via email at:
Attention: Yoel Goldfeder
Phone: 212-828-8436
Toll-Free: 855-9VSTOCK
Fax: 646-536-3179
Click here to contact investor relations.
Click here to sign up for email alerts.